- Major indications for Erythromycin
- Other organisms covered
- See Macrolide
- Gastrointestinal upset
- Nausea
- Cholestatic Jaundice
- Multiple Drug Interactions
- Candida Vaginitis infection
- Gram Negative Folliculitis
- Myasthenia Gravis exacerbation
- Hypertrophic Pyloric Stenosis (age <45 days)
-
QT Prolongation
- Class effect with Macrolides
- Three fold increased risk of Sudden Cardiac Death while on Azithromycin
- Higher risk with known QTc Prolongation, Hypokalemia, Hypomagnesemia, Class IA or III Antiarrhythmics
- Ray (2013) N Engl J Med 366(20): 1881-90 [PubMed]
- See Macrolide
- Strong CYP3A4 Inhibitor
- Numerous Drug Interactions
-
Warfarin
- May increase INR
- Half life: 1.5 hours
- See Erythromycin Ethyl Succinate (EES)
- See Erythromycin Lactobionate
- See Pertussis
- Erythromycin Oral Preparations (Take with food to reduce GI Upset)
- Erythromycin Base
- Adult: Take 250 to 500 mg orally four times daily OR 333 mg orally three times daily
- Child: Take 30 to 50 mg/kg/day divided four times daily
- Erythromycin Ethyl Succinate (EES)
- Adult: 400 mg orally four times daily
- Child: 30-50 mg/kg/day divided orally four times daily
- Erythromycin Base
- Erythromycin Parenteral Preparation: Erythromycin Lactobionate
- Dose: 15 to 20 mg/kg/day IV divided every 6 hours
- Maximum: 4 grams
- Pregnancy Category B
- Considered safe in Lactation
- Myasthenia Gravis exacerbation
- Hypertrophic Pyloric Stenosis (age <45 days)
- Strong CYP3A4 Inhibitor
- Numerous Drug Interactions
- Serious interactions resulting in death have occurred
-
Warfarin
- May increase INR
-
QT Prolongation
- Class effect with Macrolides
- Three fold increased risk of Sudden Cardiac Death while on Azithromycin
- Higher risk with known QTc Prolongation, Hypokalemia, Hypomagnesemia, Class IA or III Antiarrhythmics
- Ray (2013) N Engl J Med 366(20): 1881-90 [PubMed]
- Erythromycin Base (DailyMed)